Tuesday, November 12, 2024 at 2-3pm ET                          Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

The importance of radiotracer characteristics for diagnosis of coronary artery disease (CAD). Flyrcado^TM (F-18 flurpiridaz)

The significant clinical and economic burden of CAD highlights the need for accurate and timely diagnosis. Current imaging methods present challenges and limitations that can potentially lead to inconclusive or false results, thereby impacting diagnosis and downstream healthcare resource utilization.

This webinar will provide a comprehensive overview of current CAD diagnostic imaging, describe the burden of disease, and illustrate limitations and unmet needs posed by existing Myocardial Perfusion Imaging (MPI) modalities in the United States.

The webinar will then introduce Flyrcado^TM (F-18 flurpiridaz), a recent FDA approved PET-MPI radiotracer indicated to diagnose coronary artery disease (CAD) and discuss how Flyrcado^TM may play a role in optimizing the diagnosis of CAD in some difficult-to-image patient subgroups.

Learning Objectives

• Understand the main principles and challenges for the diagnostic imaging of Coronary Artery Disease (CAD), including disease burden, barriers, and limitations of current modalities.
• Review the current landscape of Myocardial Perfusion Imaging modalities (MPI) benefits, barriers, and constraints of current modalities and radiotracers.
• Understand how Flyrcado^TM can help to optimize the imaging and diagnosis of CAD, and how it addresses ongoing unmet needs posed by existing modalities and tracers.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.